Takeda Consumer Healthcare presented data during the 48th Society for Neuroscience annual meeting on the novel effect of Fursultiamine in promoting voluntary physical activity
- December 25, 2018
We hereby announce that we presented data during the 48th Society for Neuroscience (SfN) annual meeting taking place in San Diego from November 3 to 7, 2018, on the novel effect of Fursultiamine (thiamine tetrahydrofurfuryl disulfide) *, a vitamin B1 derivative. The data, which were obtained through joint research with the University of Tsukuba, showed that Fursultiamine increases dopamine release in the brain (particularly in the medial prefrontal cortex) and enhances voluntary physical activity.
We will continue to study Fursultiamine in the future.
Thiamine tetrahydrofurfuryl disulfide promotes voluntary locomotor activity through dopaminergic activation in the medial prefrontal cortex.
November 3, 2018, 1:00–5:00 PM
San Diego Convention Center Hall C
*Fursultiamine is a vitamin B1 derivative developed by Takeda. Unlike ordinary vitamin B1, it has a superior absorption rate, transfers well into tissues, and produces increased amounts of active vitamin B1 in a form suitable for working in our body.
(A derivative, an organic-chemistry term, is a compound that is obtained after the structure of an organic compound (vitamin B1 here) is partially altered)